PURPOSE: To assess the effect of tumor detection method (screening versus symptom-based diagnosis) in predicting breast cancer survival and investigate how biological features of breast cancer are related to the tumor detection method. PATIENTS AND METHODS: The study population consisted of 5,481 women diagnosed with primary invasive breast cancer between 1997 and 2005 and received their treatment at The University of Texas M. D. Anderson Cancer Center. RESULTS: Patients with symptom-detected tumors had an increased risk of recurrence or death [relative risk (RR), 1.34; P = 0.006] and breast cancer-specific death (RR, 1.31; P = 0.117) than patients with screen-detected tumors after adjusting for tumor characteristics and treatments received. This relationship was especially evident among estrogen receptor (ER)-negative tumors (RR, 1.60 for breast cancer recurrence for ER-negative tumors; RR, 1.18 for ER-positive tumors). ER status and Ki-67 expression were statistically significantly associated with symptom detection rate after adjusting for patients' age, tumor stage, tumor size, and nuclear grade [odds ratio (OR) of ER negative versus ER positive, 1.35; P < 0.001; OR of Ki-67 10-30% versus <10%, 1.40; P = 0.005; OR of Ki-67 >30% versus <10%, 2.11; P < 0.001]. CONCLUSION: The method of detection was a statistically significant independent predictor of breast cancer recurrence. Information on the method of tumor detection should be collected to improve the prediction of prognosis of breast cancer patients.
PURPOSE: To assess the effect of tumor detection method (screening versus symptom-based diagnosis) in predicting breast cancer survival and investigate how biological features of breast cancer are related to the tumor detection method. PATIENTS AND METHODS: The study population consisted of 5,481 women diagnosed with primary invasive breast cancer between 1997 and 2005 and received their treatment at The University of Texas M. D. Anderson Cancer Center. RESULTS:Patients with symptom-detected tumors had an increased risk of recurrence or death [relative risk (RR), 1.34; P = 0.006] and breast cancer-specific death (RR, 1.31; P = 0.117) than patients with screen-detected tumors after adjusting for tumor characteristics and treatments received. This relationship was especially evident among estrogen receptor (ER)-negative tumors (RR, 1.60 for breast cancer recurrence for ER-negative tumors; RR, 1.18 for ER-positive tumors). ER status and Ki-67 expression were statistically significantly associated with symptom detection rate after adjusting for patients' age, tumor stage, tumor size, and nuclear grade [odds ratio (OR) of ER negative versus ER positive, 1.35; P < 0.001; OR of Ki-67 10-30% versus <10%, 1.40; P = 0.005; OR of Ki-67 >30% versus <10%, 2.11; P < 0.001]. CONCLUSION: The method of detection was a statistically significant independent predictor of breast cancer recurrence. Information on the method of tumor detection should be collected to improve the prediction of prognosis of breast cancerpatients.
Authors: Suzie J Otto; Jacques Fracheboud; Caspar W N Looman; Mireille J M Broeders; Rob Boer; Jan H C L Hendriks; André L M Verbeek; Harry J de Koning Journal: Lancet Date: 2003-04-26 Impact factor: 79.321
Authors: Heikki Joensuu; Tiina Lehtimäki; Kaija Holli; Liisa Elomaa; Taina Turpeenniemi-Hujanen; Vesa Kataja; Ahti Anttila; Mikael Lundin; Jorma Isola; Johan Lundin Journal: JAMA Date: 2004-09-01 Impact factor: 56.272
Authors: Hannah K Weir; Michael J Thun; Benjamin F Hankey; Lynn A G Ries; Holly L Howe; Phyllis A Wingo; Ahmedin Jemal; Elizabeth Ward; Robert N Anderson; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2003-09-03 Impact factor: 13.506
Authors: Brian L Sprague; Ronald E Gangnon; John M Hampton; Kathleen M Egan; Linda J Titus; Karla Kerlikowske; Patrick L Remington; Polly A Newcomb; Amy Trentham-Dietz Journal: Am J Epidemiol Date: 2015-05-05 Impact factor: 4.897
Authors: Rowan T Chlebowski; JoAnn E Manson; Garnet L Anderson; Jane A Cauley; Aaron K Aragaki; Marcia L Stefanick; Dorothy S Lane; Karen C Johnson; Jean Wactawski-Wende; Chu Chen; Lihong Qi; Shagufta Yasmeen; Polly A Newcomb; Ross L Prentice Journal: J Natl Cancer Inst Date: 2013-03-29 Impact factor: 13.506
Authors: A M Brewster; P Thompson; A A Sahin; K Do; M Edgerton; J L Murray; S Tsavachidis; R Zhou; Y Liu; L Zhang; G Mills; M Bondy Journal: Cancer Prev Res (Phila) Date: 2011-07-27
Authors: Deirdre A Hill; Andrea Nibbe; Melanie E Royce; Anne Marie Wallace; Huining Kang; Charles L Wiggins; Robert D Rosenberg Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09-14 Impact factor: 4.254
Authors: Rowan T Chlebowski; Garnet L Anderson; Margery Gass; Dorothy S Lane; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Marcia L Stefanick; Judith Ockene; Gloria E Sarto; Karen C Johnson; Jean Wactawski-Wende; Peter M Ravdin; Robert Schenken; Susan L Hendrix; Aleksandar Rajkovic; Thomas E Rohan; Shagufta Yasmeen; Ross L Prentice Journal: JAMA Date: 2010-10-20 Impact factor: 56.272
Authors: Tiina Lehtimäki; Mikael Lundin; Nina Linder; Harri Sihto; Kaija Holli; Taina Turpeenniemi-Hujanen; Vesa Kataja; Jorma Isola; Heikki Joensuu; Johan Lundin Journal: Breast Cancer Res Date: 2011-12-28 Impact factor: 6.466
Authors: Francesco Sardanelli; Hildegunn S Aase; Marina Álvarez; Edward Azavedo; Henk J Baarslag; Corinne Balleyguier; Pascal A Baltzer; Vanesa Beslagic; Ulrich Bick; Dragana Bogdanovic-Stojanovic; Ruta Briediene; Boris Brkljacic; Julia Camps Herrero; Catherine Colin; Eleanor Cornford; Jan Danes; Gérard de Geer; Gul Esen; Andrew Evans; Michael H Fuchsjaeger; Fiona J Gilbert; Oswald Graf; Gormlaith Hargaden; Thomas H Helbich; Sylvia H Heywang-Köbrunner; Valentin Ivanov; Ásbjörn Jónsson; Christiane K Kuhl; Eugenia C Lisencu; Elzbieta Luczynska; Ritse M Mann; Jose C Marques; Laura Martincich; Margarete Mortier; Markus Müller-Schimpfle; Katalin Ormandi; Pietro Panizza; Federica Pediconi; Ruud M Pijnappel; Katja Pinker; Tarja Rissanen; Natalia Rotaru; Gianni Saguatti; Tamar Sella; Jana Slobodníková; Maret Talk; Patrice Taourel; Rubina M Trimboli; Ilse Vejborg; Athina Vourtsis; Gabor Forrai Journal: Eur Radiol Date: 2016-11-02 Impact factor: 5.315